NICE recommends lisocabtagene maraleucel cell therapy for eligible patients with relapsed or refractory large B-cell lymphomas
Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
Massive data analysis advances the understanding of how immunotherapy works
What factors influence the success or failure of immunotherapy treatment in patients with advanced bladder…
New hope for colorectal cancer treatment: Innovative CE6-GFFY photosensitiser
Many strategies have been employed for clinical colorectal cancer (CRC) therapy. However, current treatments face significant…
Can exercise help colon cancer survivors live as long as matched individuals in the general population?
Physical activity may help colon cancer survivors achieve long-term survival rates similar to those of…
ASCO GU 2025: New findings on tumour reduction and survival outcomes in advanced renal cell carcinoma
Thomas E. Hutsonchief of the Haematology Oncology Division at Texas Tech University Health Sciences Centre,…
Rare side effect of cancer immunotherapy
Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that…
Article details drug’s lack of benefit for head and neck cancer
A physician-scientist at the University of Oklahoma, USA, is part of an international effort seeking…
Study finds focused ultrasound therapy improves cancer treatment
Combining an existing small-molecule protein therapy called tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) with focused…
NICE recommends rucaparib as a first-line maintenance treatment for BRCA-negative advanced ovarian cancer
Pharma and GmbH announced today that the UK’s National Institute of Health and Care Excellence…
New technique to measure circulating tumour DNA in metastatic cancer may improve disease progression surveillance and patient outcomes
In metastatic cancer surveillance, monitoring the actual concentrations of circulating tumour DNA (ctDNA) may be…